Inflammatix Receives FDA Clearance for First-in-Class TriVerity™ Test
First and only molecular blood test that can both identify bacterial and viral infections and assess need for critical care
Precision medicine approach aims to transform emergency triage standard of care
TriVerity expected to enable timely and confident decision-making for emergency departments
SUNNYVALE, Calif., Jan. 21, 2025 /PRNewswire/ — Inflammatix, a pioneering host response diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for the TriVerity™ Test System (TriVerity), a first-in-class molecular test for patients with suspected acute infection or sepsis. Using precise measurements of a patient’s immune response, TriVerity combines highly accurate bacterial-viral infection scoring with an all-cause illness severity risk evaluation, giving clinicians a rapid and holistic snapshot of a patient’s status.
